3.11 Drugs Used for Angina – Nitrates

John Smithson

In this topic we will look at organic nitrates and explore their use in a clinical setting.

Introduction – Organic Nitrates

The organic nitrates are effective dilators of (predominantly) veins and arteries and are used to treat angina pectoris. Organic nitrates can be classed into two broad groups:

  • Short acting rapid onset nitrates: glyceryl trinitrate and isosorbide dinitrate
  • Longer acting slower onset nitrates: isosorbide mononitrate.

Short and long acting nitrates are both used to manage angina, but are used at different times. The short acting – rapid onset sublingual glyceryl trinitrate and isosorbide dinitrate are used to manage acute symptoms of unstable angina or for the prevention of symptoms of angina. The longer acting nitrates isosorbide mononitrate (and controlled release isosorbide dinitrate and glyceryl trinitrate patch) are used to prevent symptoms of chronic angina. The order of relative duration of action of the different nitrates can be remembered by the number of nitrate groups in the preparation:

  • trinitrate (3) is short acting
  • dinitrates (2) slightly longer acting
  • mononitrates (1) long acting.

Endogenous (naturally produced) nitric oxide is produced by vascular endothelial cells (other cells too but they are less important at the moment) and has a range of important functions. One of these functions is to mediate relaxation of vascular smooth muscle. Nitric oxide (NO) moves from the endothelial cell and enters the smooth muscle cell where it binds with soluble guanylyl cyclase which converts GTP to cGMP. cGMP activates Protein Kinase G which phosphorylates myosin and causes smooth muscle relaxation.

📺 Watch the YouTube video on the role of NO in smooth muscle relaxation. Watch from 4min: 16 seconds to the end of the video. Video available at https://www.youtube.com/watch?v=8ZbzSLFuLdY (3:30 min)

The organic nitrates donate a nitrate group where it is converted to nitric oxide by s-nitrosothiol to nitric oxide. Nitric oxide (NO) binds with soluble guanylyl cyclase which converts GTP to cGMP. cGMP activates Protein Kinase G which phosphorylates myosin and causes smooth muscle relaxation.

Klabunde, R. General Pharmacology. National Library of Medicine (US); 2007 [updated 2012 July 11; cited 2020 March 7]. Available from: https://cvpharmacology.com/vasodilator/nitro.
Figure 3.11.1: Action of exogenous nitrates – dontates a NO group which is a cofactor for the conversion of GTP to cGMP. Increased levels of cGMP cause relaxation of vascular smooth muscle. Image taken from Klabunde, R. General Pharmacology. National Library of Medicine (US); 2007 [updated 2012 July 11; cited 2020 March 7]. Available from: https://cvpharmacology.com/vasodilator/nitro.

At therapeutic doses of nitric oxide, the dilation of veins predominates over arteries.  The vasodilatation of veins (+++ lots) and arteries (+ a bit) has 2 major effects:

It is the reduction in ventricular pre-load and resultant reduction of myocardial oxygen demands that explains its benefit in stable angina (pectoris), rather than it’s dilation of the coronary arteries.

Side effects include orthostatic hypotension, headache, flushing, palpitations, hypotension and peripheral oedema. Patients can build a tolerance to nitrates with continuous exposure. This can be avoided by ensuring patients have nitrate-free period of at least 8-hours in each 24-hour period.

Kinetics. Most organic nitrates have low oral bioavailability as they undergo extensive first pass metabolism. The one exception is isosorbide mononitrate which has quite high oral bioavailability. Because the bioavailability of the other organic nitrates are low, they are typically administered by sublingual tablet or spray, patch or infusion.

📺 Watch the vodcast on the Pharmacology of nitrates. (6:03 minutes) 

Summary

  • The organic nitrates donate a nitrate group providing an exogenous (artificial) source of nitric oxide to cause vasodilatation. 
  • This results in a reduction of available cytosolic calcium and decreased venous (and arterial to a lesser extent) contraction.
  • This results in a decrease in preload and therefore myocardial oxygen demand, rebalancing the supply-demand mismatch that explains angina.
  • Organic nitrates can be grouped into short and long-acting classes.
  • The useful effect in angina comes from the reduction in pre-load rather than the physical dilatation of the coronary arteries.

 

COMMONWEALTH OF AUSTRALIA Copyright Regulations 1969 WARNING

This material has been reproduced and communicated to you by or on behalf of James Cook University in accordance with section 113P of the Copyright Act 1969 (Act).

The material in this communication may be subject to copyright under the Act. Any further reproduction or communication of this material by you may be the subject of copyright protection under the Act. Do not remove this notice.

 

License

MD2012 - Medical Pharmacology Copyright © by John Smithson. All Rights Reserved.